July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Cytotoxicity of Lactoferrin loaded Carboplatin and Etoposide drug delivery in Y79 Rb cell line and cancer stem cells
Author Affiliations & Notes
  • Geeta K Vemuganti
    School of Medical Sciences, University of Hyderabad, Hyderabad, ANDHRA PRADESH, India
  • Narayana RVL
    School of Medical Sciences, University of Hyderabad, Hyderabad, ANDHRA PRADESH, India
  • Rohini M Nair
    School of Medical Sciences, University of Hyderabad, Hyderabad, ANDHRA PRADESH, India
  • Neha Tomar
    Department of biotechnology and Bioinformatics, University of Hyderabad, Hyderabad, TELANGANA, India
  • Anand Kumar Kondapi
    Department of biotechnology and Bioinformatics, University of Hyderabad, Hyderabad, TELANGANA, India
  • Swathi Kaliki
    The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, TELANGANA, India
  • Footnotes
    Commercial Relationships   Geeta Vemuganti, None; Narayana RVL, None; Rohini Nair, None; Neha Tomar, None; Anand Kondapi, None; Swathi Kaliki, None
  • Footnotes
    Support  UGC-UKIERI-2017
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1634. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Geeta K Vemuganti, Narayana RVL, Rohini M Nair, Neha Tomar, Anand Kumar Kondapi, Swathi Kaliki; Cytotoxicity of Lactoferrin loaded Carboplatin and Etoposide drug delivery in Y79 Rb cell line and cancer stem cells. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1634.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cancer stem cells (CSCs) in all tumors including Retinoblastoma (Rb) are known to be chemoresistant and lead to tumor relapse after treatment in addition to being tumorigenic and metastatic in nature. Our previous studies identified CD133lo subset to be the CSCs in primary tumor as well as in Rb Y79 cell line. In this study, we aimed to evaluate the cytotoxicity of nanoformulated cancer drugs (Carboplatin and Etoposide) using lactoferrin protein nanoparticlesinY79Rb cell line and CD133sorted populations.

Methods : Carboplatin and Etoposide loaded nanoparticles were prepared using the solution-oil chemistry based method. The drug and lactoferrin were measured 1:4 ratio, dissolved in PBS and incubated on ice for 60 min. 25ml of olive oil was added and further incubated on ice for 30min. After sonication for 15min at 60Amp, the mixture was frozen in liquid N2 for 10min and immediately transferred to 4oC for 4hrs. The pellet obtained on centrifugation was resuspended in 500µlPBS, characterized using SEM and measured for drug release efficiency using HPLC. Cytotoxicity of the standard and nanoformulated drugs was evaluated by MTT assay in total Y79 cellsand CD133 sorted subsets (CSCs and non-CSCs) with an exposure period of 48 hrs.

Results : Carboplatin and Etoposide loaded lactoferrin protein nanoparticles measured 60±10 nm, 45±10nm and 25±5nm respectively. Drug loading efficiency of Carboplatin and Etoposide release in pH-5.2 was 60+5 and 48+5 respectively. The efficiency of nanoformulations of both the drugs had higher efficacy in all the three populations (p<0.05) starting with 50µM dose. CD133lo cells which constituted 15±0.6% of total population exhibited lower drug cytotoxicity as compared to total and non-CSCs (CD133hi) cells (p<0.05).

Conclusions : This study provides evidence of higher cytotoxic efficacy of nanoformulated Carboplatin and Etoposide on Rb Y79 cell lines as compared to the standard soluble formulation in-vitro.Evidence of lower cytotoxic effect of drugs on CD133lo as compared toCD133hipoints towards chemoresistance, s characteristic of CSCs, in CD133lo population cells in Rb cell line, thus supporting our earlier studies. Further validation using combination and in-vivo testing are warranted to pave way for potential clinical application.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×